The inhalation device influences lung deposition and bronchodilating effect of terbutaline

American Journal of Respiratory and Critical Care Medicine

Volumn 153, Issue 5, 1996, Pages 1636-1640

  Borgström, Lars ^b   Derom, Eric ^b   Ståhl, Elisabeth ^b   Wåhlin Boll, Elisabeth ^b   Pauwels, Romain ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TERBUTALINE SULFATE;

ADULT; AEROSOL; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029972560     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.153.5.8630614     Document Type: Article

References (32)

1. National Heart, Lung, and Blood Institute, National Institutes of Health. 1992. International Consensus Report on Diagnosis and Treatment of Asthma. Eur. Respir. J. 5:601-641.
2. Epstein, S. W., C. P. R. Manning, M. J. Ashley, and P. N. Corvey. 1979. Survey of the clinical use of pressurized aerosol inhalers. Can. Med. Assoc. J. 120:813-816.
3. x interaction. Nature 315:207-210.
4. Newman, S. P. 1990. Metered dose pressurized aerosols and the ozone layer. Eur. Respir. J. 3:495-497.
5. Pavia, D., and L. McLeod. 1994. The environmental impact of inhaled aerosols. Eur. Respir. J. 4:75-77.
6. Pierce, R. J., J. P. Scale, R. E. Ruffin. 1991. Inhaled respiratory medication and the use of chlorofluorocarbons. Med. J. Aust. 201:701-704.
7. Borgström, L., S. Newman, A. Weisz, and F. Morén. 1992. Pulmonary deposition of terbutaline: comparison of scanning gamma camera and urinary excretion methods. J. Pharm. Sci. 81:753-755.
8. Borgström, L. 1993. Methodological studies on lung deposition: evaluation of inhalation devices and absorption mechanisms. Acta Universalis Upsaliensis, Upsala. 7-19.
9. Borgström, L., and M. Nilsson. 1990. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm. Res. 7:1068-1070.
10. Engel, T., J. H. Heinig, F. Madsen, and K. Nikander. 1990. Peak inspiratory flow and vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur. Respir. J. 3:1037-1041.
11. Newman, S. P., F. Morén, E. Trofast, N. Talaee, and S. W. Clarke. 1991. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. 1991. Int. J. Pharm. 74:209-213.
12. Newman, S. P., D. Pavia, N. Garland, and S. W. Clarke. 1982. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur. J. Respir. Dis. 63(Suppl. 19):57-65.
13. Dolovich, M., R. E. Ruffin, R. Roberts, and M. T. Newhouse. 1981. Optimal delivery of aerosols from metered dose inhalers. Chest 80 (Suppl. 6):911-915.
14. 3H-terbutaline (Bricanyl®) in mice. Acta Physiol. Scand. 84:40-47.
15. Briant, R. H., E. W. Blackwell, F. M. Williams, D. S. Davies, and C. T. Dollery. 1973. The metabolism of sympathomimetic bronchodilator drugs by the isolated perfused dog lung. Xenobiotica 3:787-799.
16. Borgström, L., C. Lindberg, S. Jönsson, and K. Svensson. 1988. Comparative pharmacokinetics of unlabeled and deuterium-labeled terbutaline: demonstration of a small isotope effect. J. Pharm. Sci. 77: 952-954.
17. Borgström, L., L. Nyberg, S. Jönsson, C. Lindberg, and J. Paulson. 1989. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br. J. Clin. Pharmacol. 27: 49-56.
18. Thorsson, L., S. Edsbäcker, and T.-B. Conradson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from pressurised metered dose inhaler (P-MDI). Eur. Respir. J. 7:1839-1844.
19. Fuglsang, G., and S. Pedersen. 1989. Comparison of a new multidose powder inhaler with a pressurised aerosol in children with asthma. Pediatr. Pulmonol. 7:112-115.
20. Auty, R. M., K. Brown, M. G. Neale, and P. D. Snashall. 1987. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br. J. Dis. Chest 87:371-380.
21. Vidgren, M., A. Kärkkäinen, P. Karjalainen, P. Paronen, J. Nuutinen. 1988. Effect of powder inhaler design on drug deposition in the respiratory tract. Int. J. Pharm. 42:211-216.
22. 99mTc-labelled salbutalmol. Journal of Aerosol Medicine 4(Suppl. 1):9.
23. Biddiscombe, M. F., R. Melchor, V. H. F. Mak, R. J. Marriot, A. J. Taylor, and M. D. Short. 1993. The lung deposition of salbutamol, directly labelled with technetium-99m, delivered by pressurised metered dose and dry powder inhalers. Int. J. Pharm. 91:111-121.
24. Zainudin, B. M. Z., M. Biddiscombe, S. E. J. Tolfree, M. Short, and S. G. Spiro. 1990. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 45: 469-473.
25. Newman, S. P. 1993. Scintigraphic assessment of therapeutic aerosols. Crit. Rev. Ther. Drug Carrier Syst. 10:65-109.
26. 99mTc-DTPA from the bronchial mucosa. Am. Rev. Respir. Dis. 139:1132-1138.
27. Dolovich, M., E. Churchill, and M. Newhouse. 1993. Comparison of the response to salbutamol and terbutaline sulphate administered by MDI or DPI in asthmatic subjects (abstract). Am. Rev. Respir. Dis. 147:A58.
28. Tonnesen, F., L. C. Laursen, T. Evald, E. Ståhl, and T. Ibsen. 1994. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 105:697-700.
29. 2-agonists. Clin. Exp. Allergy 22:600-605.
30. Agertoft, L., and S. Pedersen. 1993. Importance of the inhalation device on the effect of budesonide. Arch. Dis. Child. 69:130-133.
31. Toogood, J. H., B. Jennings, R. W. Greenway, and L. Chuang. 1980. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol. 65:145-153.
32. Toogood, J. H., B. Jennings, J. Baskerville, J. Anderson, and S. A. Johansson. 1984. Dosing regimen of budesonide and occurrence of oropharyngeal complications. Eur. J. Respir. Dis. 65:35-44.